News Releases | Page 2 of 1285 | Follow The Money Investor Group

1933 INDUSTRIES SIGNS STRATEGIC MANAGEMENT AGREEMENT TO EXPAND ITS BRANDS INTO CALIFORNIA, THE LARGEST CANNABIS MARKET IN THE WORLD

August 15, 2019 – 1933 Industries Inc. (the “Company” or “1933 Industries”) (CSE: TGIF) (OTCQX: TGIFF) is pleased to announce that it has signed a Management Services Agreement (“Agreement”) to provide operational and accounting services, general management and oversight to Green Spectrum Trading, Inc. (“Green Spectrum”), a medicinal and recreational cannabis business licensee in the State of California, for a two-year term. Green Spectrum operates as a licensed cannabis cultivator, manufacturer and distributor, and holds a pending home delivery business license.

Crystal Lake Extends Burgundy Ridge Discovery to Depth, Adds Second Drill Rig at Newmont Lake Project

August 12, 2019, Vancouver, British Columbia – Crystal Lake Mining Corporation (TSXV: CLMOTC: SIOCF FSE: SOG-FF) (“Crystal Lake” or the “Company”) is pleased to announce that shallow mineralization encountered in first-ever drilling at Burgundy Ridge last fall (four reverse circulation test holes, see March 7, 2019 news release) has deep roots, extending well beyond a copper-gold enriched limestone body as maiden diamond drilling continues at this new grassroots discovery in Northwest B.C.’sEskay Camp.

Garibaldi Drills 18 Meters of Massive Sulphide Within 86-Meter Interval at Nickel Mountain Discovery

Aug. 9, 2019 /CNW/ - Garibaldi Resources (TSXV: GGI) (the "Company" or "Garibaldi") is pleased to provide the following update as two drill rigs continue to aggressively build out Northwest British Columbia's first magmatic nickel-copper-rich massive sulphide discovery in the heart of the Eskay Camp near the past producing Eskay Creekmine.

PreveCeutical Grants Asterion Option to Purchase up to a 51% Interest in Sol-Gel Intellectual Property

August 6, 2019 PreveCeutical Medical Inc. (“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), and Asterion Cannabis Inc. (“Asterion”) announce that they have entered into an option to purchase agreement (the “Option Agreement”), whereby PreveCeutical has granted to Asterion the right and option (the“Option”) to purchase up to 51% of PreveCeutical’s right, title and interest in and to certain intellectual property rights relating to a soluble gel (“Sol-Gel”) nasal delivery system for the nose-to-brain delivery of therapeutic formulations, including cannabis and cannabinoids (the “Sol-Gel IP”).